Biocon owns the molecule and the plant. It owns neither the licence nor the customer. In Japan that is a routine structure, and it is worth understanding what it costs before treating it as free.

• Three parties, and Biocon touches neither end of the chain. Japan requires a domestic marketing authorisation holder, so manufacturers without a local entity appoint an in-country caretaker. Of the 3 functions, Biocon holds only manufacture, and has no direct regulatory relationship with the authority. Every label change, safety signal and supply interruption routes through someone else.
• The distributor develops the same product classes. Sandoz is among the largest biosimilar companies in the world, and it now controls promotion, sale and distribution, all 3 functions, exclusively. That is a decision with a shelf life. Read the exit and change-of-control terms before the launch terms.
• Treat the split structure as the Japanese default, not the exception. Two approvals in a fortnight, 25 August in both cases, with the authorisation held by a third party. Anyone modelling Japanese entry should assume a caretaker MAH and a local commercial partner, and should price the margin stack accordingly.